MRI Assessment of iron overload in thalassemia: an overview

Kavita Sagar¹, Praveen Sobti²

¹ Department of Radiodiagnosis and ² Department of Paediatrics, Dayanand Medical College, Ludhiana (India).

MRI Assessment of iron overload in thalassemia: an overview

β thalassemia major is a hereditary hemolytic disorder treated with multiple blood transfusions. The main complication of this treatment is iron overload initially in the reticuloendothelial system, joints and then in all parenchyma, especially the heart, liver, and endocrine organs. Increased iron deposition has a cytotoxic effect, leading to cell death and organ dysfunction. Measures of plasma ferritin levels and hepatic iron level are used for assessing body iron overload. Direct assessment of iron deposition in different organs necessitates tissue biopsy, which is not always possible. Magnetic Resonance Imaging (MRI) is a reliable & non-invasive tool for assessing tissue siderosis. With the advent of increasing options for iron chelation therapy, MRI can guide clinicians to more appropriately tailor chelation therapy to individual patient needs, producing greater efficacy with less toxicity. Future research in MRI monitoring aims at improved prevention of endocrine toxicities, particularly hypogonadotropic hypogonadism and diabetes.

Key words: Magnetic resonance, thalassemia, iron overload, liver, heart, endocrine glands.
Introduction

β-Thalassaemia major is a hereditary haemolytic anaemia that is treated with multiple blood transfusions. A major complication of this treatment is iron overload, which has cytotoxic effect & leads to cell death and organ dysfunction. Chelation therapy, used for iron elimination, requires effective monitoring of the body burden of iron (1). Many centers rely exclusively on serum ferritin to track somatic iron stores. Whereas trends in serum ferritin remain an important monitoring tool, serum ferritin is a poor marker of iron balance because it varies with inflammation, ascorbate status, and intensity of transfusion therapy. Liver iron measurement by biopsy is more accurate but its invasiveness limits routine screening at most institutions. The desire to replace liver biopsy with a noninvasive test drove the earliest studies on magnetic resonance imaging (MRI) iron quantification (2).

Physics of MRI tissue iron assessment

The use of MRI to estimate tissue iron was conceived in the early 1980s, but did not become practical until MRI technology matured 20 years later (2). The general concept is simple (3). MRI machines can generate images at various observation or “echo” times to vary the contrast among different organs. All organs darken with increasing echo time, but those containing iron darken more rapidly. This is due to the fact that, the magnetic field in a clinical scanner is extremely homogenous, but iron within the tissues creates local magnetic field disturbances that cause the images to darken faster. T2* represents the echo time necessary for a tissue to become twice as dark. Alternatively, image darkening can be expressed by R2*, its rate of darkening. Some investigators prefer to report R2* values rather than T2* values, because R2* is directly proportional to iron concentration (4, 5). R2* values are simply 1000/T2* and vice versa, making it easily to convert one representation to another (6).

MRI scanners can also collect images suitable for T2 (and R2) analysis instead of T2* analysis, using radiofrequency pulse rather than magnetic gradients to generate images at different echo times. Image analysis and iron quantification is similar whether using R2 or R2* images. R2 images take longer to collect and are used more frequently to evaluate liver iron concentration (LIC) (6). Whereas cardiac T2 imaging is also possible, it is more challenging because of respiratory motion, limiting its widespread acceptance (7).

MRI Field strength

Although most 1.5 Tesla magnets are intrinsically able to perform iron estimation measurements, specialized software and local expertise/training are required for accurate assessment. As a result, some centers have chosen to purchase commercial software or outsource their image analysis to fee-for-service vendors rather than commit the resources to obtain the measurements themselves. Published iron calibration curves are available for liver R2, liver R2*, and cardiac R2* measurements at 1.5 Tesla. Calibration refers to the mathematical association between MRI measurements and underlying tissue iron concentration (7).

Relaxation rates R2 and R2* increase with field strength. Because of the dependency of relaxation rates on field strength, calibration curves obtained at one field strength (e.g., 1.5T) cannot be transferred directly to another field strength (e.g., 3T). Thus, calibration curves at different field strengths should be derived and validated. Also, whereas 3T imaging provides higher signal to noise than 1.5T, it has theoretical disadvantages for LIC estimation. For example, susceptibility artifacts are worse at 1.5T, which may degrade GRE image quality. More importantly, owing to faster signal decay at 3T, the maximum quantification limit may be lower than at 1.5T, potentially lowering the utility of 3T scanners for iron quantification (8).

MR methodologies

MR methods for assessing tissue iron can be separated into two groups: signal intensity ratio (SIR) methods and relaxometry methods. Various techniques have been described, including: (a) methods measuring SIR based on T2-weighted (spin-echo) or T2*-weighted (gradient-echo) sequences (9, 10-19), (b) relaxometry methods measuring absolute T2, (c) relaxometry methods measuring absolute T2*, and (d) hybrid relaxometry methods (14, 15, 20-26).
SIR methods

These have been used for the study not only of the liver but also of other organs such as the spleen, pancreas, pituitary gland, bone marrow and abdominal lymph nodes (9, 10, 12, 14-19, 27). For SIR assessment the signal intensity of the target organ is divided by the signal intensity of a reference tissue (e.g. fat, muscle) or noise. Signal intensity measurements are performed in the same slice by using the region-of-interest (ROI) method. For large organs such the liver, spleen and pancreas more than one ROI is used, positioned in areas lacking vascular structures and movement artefacts (9, 10, 12, 14, 15, 18, 19, 27). The mean signal intensity from the different ROIs is then divided by the signal intensity of the reference tissue (1).

A disadvantage of the SIR methods is that in most cases they use only one echo time (TE) and thus lose their detection sensitivity in tissues with heavy siderosis, where transverse relaxation is much faster than the TE. This occurs particularly in the liver at the upper range of LIC values where signal intensities are widely dispersed (28).

Gardon, et al. (9) by using an algorithm that combined signal intensity ratios from multiple sequences with different TE's, achieved extension of the detection range up to about 21 mg Fe per gram dry liver tissue, with sensitivity and specificity similar to those of biochemical analysis.

T2 relaxometry methods

These assess T2 relaxation time or R2 (1/T2) by using the Carr-Purcell-Meiboom-Gill (CPMG) spin-echo sequence, which employs multiple (2-32) equidistant refocusing 180° pulses, each followed by an echo (29, 30). Most scanners, by using a pixel-by-pixel, log-linear fitting model, automatically derive the corresponding T2 maps. Signal intensity measurements in the T2 maps correspond to the mean T2 relaxation time of the included voxels (31).

A T2 relaxometry method that received FDA approval for clinical liver iron estimation has recently been developed by St. Pierre, et al. This method uses multiple T2-weighted single spin-echo sequences with different TE's acquired in half-Fourier mode to reduce acquisition time. The calculated mean R2 values combined with LIC values, obtained from liver biopsies, are used to create calibration curves (1).

T2* relaxometry methods

These evaluate T2* or R2* by using multiple gradient-echo sequences with different TE's. These methods have been developed to further accelerate acquisition, in order to increase sensitivity and eliminate artefacts related to respiration or cardiac motion. To obtain R2* (1/T2*) values, the signal decay curve is usually fitted with an exponential model: S=S0e -TE/T2*, where S is the net image signal intensity, TE is the echo time and S0 is a constant (32). T2* relaxometry methods have been used mainly for myocardial iron assessment and cardiac gating is always applied (23, 32-36). Breath-hold sequences have greatly eliminated motion artefacts (23, 32, 33).

Hybrid relaxometry methods

Hybrid approaches have been applied in high fields and measure both R2 and R2* to calculate the inhomogeneity factor R2*R2* - R2. These approaches assume that R2* is more specific to mechanisms of relaxation related to iron than R2 (32, 37, 38).

Comparison of the MRI methodologies. SIR versus relaxometry

SIR methods require shorter acquisition times but lack a wide range of iron assessment (26). Relaxometry methods, mainly the T2* method, by using multiple echoes create in and out of phase effects between water and fat transverse magnetization (23). Relaxometry methods, although taking longer, are preferable because they achieve a better sampling of the time domain in which relaxation mechanisms take place and lead to more precise results (26).

MRI studies of individual iron overloaded organs

The degree of siderosis, the crystalline structure of ferritin, the rate of iron elimination under chelation therapy and the degree of ferrooxamine formation are all organ-specific (1). All these parameters may be responsible for differences in the T2 relaxation enhancement induced in the various organs. Individual organs should be considered separately, and the effect of age on iron overload should be taken into account. Higher
survival probabilities have been reported in patients with thalassaemia born in the last 30 years. Patient compliance with treatment regimens and effective chelation therapy are thought to be the main factors associated with improved survival (39). The combination of DFO, deferasirox and the new oral chelators is considered very promising, but will require effective monitoring by non-invasive methods (40). An increasing number of studies have evaluated iron in the various affected organs by MRI (1).

**MRI assessment of Liver**

For the MRI evaluation of liver siderosis both SIR and relaxometry techniques have been used (10, 21, 32, 41-44). R2 of the liver demonstrates a significant positive correlation with serum ferritin and LIC determined from liver biopsy material (10, 21, 28, 32, 41, 43, 45). Comparative evaluation of hepatic R2 and R2* in iron overloaded patients demonstrates that both parameters correlate closely with LIC (44). Liver R2* images are the easiest and quickest to collect, but require specialized software to generate R2* and iron estimates. The upper limit of liver iron that can be reliably estimated by R2* depends on scanner specifications, but is generally 30-40 mg/g dry weight at 1.5 Tesla (7). The relationship of SIR with LIC and serum ferritin varies among studies (14, 15, 41). In most studies R2 and SIR show a better correlation with LIC than with serum ferritin (10, 21, 32, 41-44). This can be explained in part because the HCV-positive thalassaemia patients in the studies had higher serum ferritin levels than those who were HCV-negative (46, 47). Liver R2 shows no association with the hepatic inflammation histological activity index or the type of hepatitis (chronic persistent or chronic active), but is affected by hepatic fibrosis (28, 41, 46).

In iron overload states, over 70% of body iron is found in the liver and LIC has been considered to be the best marker of total body iron burden. Based on the good correlation between hepatic R2 or SIR and LIC a number of recent studies have tested the relationship between siderosis of the liver and other organs. No correlation has been found between liver and pituitary siderosis. With regard to the heart, a correlation with liver siderosis has been found only in cases of heavy myocardial iron deposition (28, 45). This lack of correlation can probably be explained by differences in transferrin receptor concentration, iron kinetics, the crystalline structure of ferritin and the degree of organ inflammation or fibrosis (1). Furthermore, under chelation therapy with DFO intracellular paramagnetic ferroxamine is formed, which exits slowly from cells unless there is an active excretion pathway as is present in the hepatocytes (48).

Young patients with thalassaemia studied longitudinally have shown absence of substantial improvement in the MR parameters of liver siderosis under different chelation therapy regimens (49). This may be explained by the fact that liver siderosis progresses very fast in thalassaemia patients, and iron overload develops after only 2 years of transfusion therapy (50). Therapy with the most widely used chelating agent is started at the age of about 3 years, and until growth is completed DFO should not exceed a dose of 40 mg/kg per day (51). An early start to monitoring the progress of tissue iron deposition with MRI might be useful in deciding whether to begin

<table>
<thead>
<tr>
<th>Grades</th>
<th>T2* Value (ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&gt; 6.3</td>
</tr>
<tr>
<td>Mild</td>
<td>6.3-2.7</td>
</tr>
<tr>
<td>Moderate</td>
<td>2.7-1.4</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt;1.4</td>
</tr>
</tbody>
</table>

**Table 1. Grading of hepatic iron loading (GE software).**

**Figure 1.**

*Hepatic T2* Map. T2* value of 5.92 ms indicates mild hepatic iron load.*
chelation therapy at a younger age and when to introduce new chelating agents (1) (Table 1). Both T2 and T2* values should be converted to liver biopsy equivalents using established calibration curves. Prospective cardiac risk increases with severe hepatic siderosis. High liver iron (15-20 mg/g dry weight) damages liver parenchyma and increases circulating NTBI levels dramatically. Therefore, the penalty for chelator noncompliance increases at high LICs. LIC values below 5 mg/g can facilitate cardiac iron clearance with defereroxamine and deferasirox; however, no liver iron can be considered ‘safe’ from a cardiac and endocrine perspective and extrahepatic monitoring by MRI is essential (7) (Figure 1).

**MRI assessment of cardiac iron**

Cardiac R2* (or T2*) is generally measured using the same scanner and software tools as those used for the measurement of liver R2*. It is a little more labor intensive to acquire, but any center with expertise with cardiac scanning should be comfortable planning and executing the examination. Estimates of left ventricular dimensions and function can be obtained at the same time. Cardiac T2* can be converted to cardiac iron concentrations using the following equation (5):

\[ Fe = 45(T2*) - 1.22 \]

Where Fe is the cardiac iron concentration in milligrams per gram dry weight and T2* is in milliseconds.

Cardiac T2* > 20 milliseconds is considered the lower limit of normal, corresponding to a myocardial iron concentration of 1.16 mg/g. Cardiac T2* values between 10 and 20 milliseconds represent mild to moderate cardiac iron deposition. Patients with a cardiac T2* in this range rarely have heart failure, but chelation should be adjusted to facilitate cardiac iron clearance. Cardiac T2* below 10 milliseconds represents severe cardiac iron loading, with the risk of heart failure increasing sharply as T2* declines. 52 Without intensification of therapy, a patient with a T2* < 6 milliseconds has a 50% risk of developing heart failure in 1 year 7 (Table 2, Figure 2).

**MRI assessment of pancreas**

Pancreas R2* measurements can readily be obtained using the same tools and techniques used for liver R2*. Whereas they are not being used in routine clinical practice currently, pancreas R2* values offer complementary information to liver and heart iron estimates. The pancreas, like the heart, exclusively loads NTBI. The kinetics of pancreatic iron loading and unloading are intermediate between the heart and liver, making pancreas R2* a better predictor of cardiac iron than liver iron (53). Increases in pancreatic R2* can be treated as surrogates for chronic NTBI exposure and modify chelation therapy accordingly, even if cardiac and hepatic iron estimates are stable (7). Pancreas R2* values also affect cardiac MRI monitoring strategies. Because the pancreas loads earlier than heart, a pancreas R2* value < 100 Hz essentially precludes cardiac iron deposition (negative predictive value > 95%) and these patients can be followed by abdominal MRI examination only. This staged strategy can significantly reduce MRI burden (53) (Table 3).

Both pancreas and cardiac R2* are correlated

---

**Table 2.**

*Grading of Myocardial Iron loading.*

<table>
<thead>
<tr>
<th>Grades</th>
<th>T2* Value (ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&gt; 20</td>
</tr>
<tr>
<td>Mild to Moderate</td>
<td>10-20</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt; 10</td>
</tr>
</tbody>
</table>

**Figure 2.**

*Cardiac T2* = 33.25 ms which is within normal limits suggesting no iron deposition.*
with glucose intolerance and diabetes. The presence of detectable cardiac iron is a relatively good predictor of overt diabetes, but lacks sensitivity for milder glucose dysregulation. Pancreas R2* > 100 Hz is sensitive for all forms of glucose dysregulation (impaired fasting glucose, impaired glucose tolerance, and diabetes), but half of these patients will have normal glucose handling. Whether pancreas R2* conveys a prospective risk of subsequent glucose dysregulation requires additional study 7. Pancreas R2* measurements have several limitations: (1) they have not gained widespread use, (2) the staged approach to cardiac scanning has not been independently validated, (3) functional correlates require further investigation, and (4) the pancreas may be difficult to locate in older, splenectomized thalassemia major subjects because of glandular apoptosis, fatty replacement, and loss of normal anatomic landmarks (54).

MRI assessment of pituitary

With routine cardiac screening, patients are now living long enough to encounter increasing iron-mediated endocrine morbidities. Hypogonadism occurs in approximately half of thalassemia patients and has long-term consequences for fertility, bone density, and quality of life (7). Preclinical iron deposition can be detected using R2 techniques, whereas severe iron deposition is associated with decreased response to gonadotropin releasing hormone challenge (55). Shrinkage of the pituitary gland is associated with more significant, irreversible loss of gonadotrophic production (56). Further clinical validation and technical standardization is necessary before pituitary MRI can be incorporated into routine clinical monitoring, but this is an active area of research (57).

MRI assessment of adrenals

Abnormalities in adrenal function have been reported in patients with thalassaemia (58). One study evaluating adrenals for iron overload with MRI showed a significant correlation between adrenal and liver siderosis (59). MRI assessment of spleen, lymph nodes and bone marrow

In spite of the fact that the spleen, lymph nodes and bone marrow, which all contain reticuloendothelial cells, are among the first organs to be affected by iron overload, there have been very few studies evaluating their iron load in thalassaemia by MRI, and these used mainly SIR techniques (1). SIR of the spleen shows a significant correlation with serum ferritin but not with SIR of the liver (19). The absence of correlation between liver and spleen siderosis could be explained by differences in iron kinetics, by differences in the cluster size of iron proteins, by haemochromatosis gene mutations in β-thalassaemia major carriers, and by the presence of extramedullary haemopoietic tissue in the spleen (1). Intraabdominal lymph nodes in β-thalassaemia have been related to chronic hepatitis C. Lymph node siderosis correlates with liver, but not with spleen siderosis (17). In the few studies that have been reported, SIR and relaxometry methods have shown discordant results for MR parameters of bone marrow siderosis and serum ferritin (1). Normal bone marrow signal associated with liver siderosis has been reported in a few patients with thalassaemia and this may be due to differences in genotype or differences in chelation therapy regimens (16).

MRI screening protocol

Chronic packed RBC transfusion therapy increases liver iron by approximately 1 mg/mL (by dry weight) for every 15 mL/kg delivered. Therefore, patients receiving more than 10 transfusions (150 mL/kg), in the absence of significant losses, merit at least an initial scan. Cardiac iron loading is rare for patients receiving fewer than 70 units of blood, 40 so a screening abdominal examination is a reasonable initial study. Patients with high transfusion load, unknown transfusion burden, or patients with Diamond Blackfan syndrome (which exhibits early cardiac iron loading) may warrant cardiac examination on their initial visit (7).
Iron measurements should be repeated on an annual basis unless there is a clinical indication for more frequent assessment, such as the use of intensive IV deferoxamine. In patients known to be at high risk of cardiac iron, we obtain liver and cardiac studies during the same imaging session. Patients a cardiac T2* < 10 milliseconds should be evaluated at 6-month intervals given their a priori risk of cardiac decompensation (52); patients in heart failure should be scanned at 3-month intervals. Children < 7 years of age require sedation and clinicians may consider scanning every other year in this age group if trends in serum ferritin are acceptable (7).

Conclusion

Thalassemia major patients require life-long transfusion chelation to avoid premature death due to organ damage by hemosiderosis. The leading cause of death is cardiac failure, but many patients also suffer from endocrine damage such as pituitary failure, hypogonadism, diabetes mellitus, and hypothyroid and hypoparathyroidism. Even aggressive deferoxamine chelation, does not provide complete cardiac and endocrine protection. The availability of new oral iron chelating agents and T2* magnetic resonance imaging (MRI) has revolutionized thalassemia management. With the increasing options for iron chelation therapy, iron assessment by MRI can allow clinicians to more appropriately tailor chelation therapy to individual patient needs, producing greater efficacy with fewer toxicities.

References

25. Assospos A, Giakoumis A, Fragadimitri C, et al. Correlation of echocardiography parameters with cardiac magnetic reso-


Correspondence:
Kavita Saggar, MD
Dayanand Medical College - Ludhiana (India)
Email: kavita.saggar@yahoo.com